P
Praxis Precision Medicines D
D
PRAX
184.224
USD
-6.56
(-3.44%)
مغلق
حجم التداول
35,156
الربح لكل سهم
-13
العائد الربحي
-
P/E
-14
حجم السوق
4,606,921,070
العنوان: Praxis Precision Medicines
القطاع: Healthcare
الصناعة: Biotechnology
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized bya neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.